1. Home
  2. CDLX vs LITS Comparison

CDLX vs LITS Comparison

Compare CDLX & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardlytics Inc.

CDLX

Cardlytics Inc.

N/A

Current Price

$3.94

Market Cap

24.0M

Sector

Technology

ML Signal

N/A

LITS

Lite Strategy Inc.

N/A

Current Price

$1.06

Market Cap

25.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CDLX
LITS
Founded
2008
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.0M
25.7M
IPO Year
2018
2003

Fundamental Metrics

Financial Performance
Metric
CDLX
LITS
Price
$3.94
$1.06
Analyst Decision
Hold
Analyst Count
2
0
Target Price
$2.25
N/A
AVG Volume (30 Days)
36.0K
318.7K
Earning Date
05-07-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
50.13
N/A
EPS
N/A
N/A
Revenue
$233,273,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.69
52 Week High
$6.40
$2.97

Technical Indicators

Market Signals
Indicator
CDLX
LITS
Relative Strength Index (RSI) 53.46 51.36
Support Level $3.95 $0.97
Resistance Level $4.52 $1.11
Average True Range (ATR) 0.24 0.07
MACD 0.02 0.00
Stochastic Oscillator 72.30 34.01

Price Performance

Historical Comparison
CDLX
LITS

About CDLX Cardlytics Inc.

Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: